GeneriCo Pharma is a biotechnology and pharmaceutical startup founded in 2012, focused on improving lives through specialty generics. The company's unique business model revolves around collaboration, leveraging global partnerships to bring high-quality, value-driven drugs to the market. With a leadership team boasting over 200 cumulative years of experience in the pharmaceutical and generic drug industry, GeneriCo brings extensive know-how to drug development.
Their collaboration model has attracted a global team of talented leaders and scientists committed to bringing difficult-to-make generic drugs to the US and worldwide market. The company's last investment of $1.50M in a Series A round on 28 July 2015 involved notable investors including BioGenerator, Missouri Technology Corporation (MTC), and Kinsale Capital Partners.
GeneriCo's approach of fostering strong collaborations and its focus on uncompromising quality in drug development positions it as a promising player in the pharmaceutical industry, with potential for impactful growth and contribution to improving global healthcare. Their global footprint spanning Asia, India, EU, and the US, coupled with an expanding pipeline and collaborative partnerships, reflects their commitment to meeting customer needs and positively impacting lives.
